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Abstract
Objective Assimilate evidence for interventions to ameliorate negative changes in physical performance, muscle strength and
muscle quantity in hospitalised older adults.
Methods We searched for articles using MEDLINE, Embase, CINAHL and Cochrane library using terms for randomised
controlled trials, older adults, hospitalisation and change in muscle quantity, strength or physical performance. Two
independent reviewers extracted data and assessed risk of bias. We calculated standardised mean differences for changes in
muscle function/quantity pre- and post-intervention.
Results We identified 9,805 articles; 9,614 were excluded on title/abstract; 147 full texts were excluded. We included 44 stud-
ies including 4,522 participants; mean age 79.1. Twenty-seven studies (n = 3,417) involved physical activity interventions;
a variety were trialled. Eleven studies involved nutritional interventions (n = 676). One trial involved testosterone (n = 39),
two involved Growth Hormone (n = 53), one involved nandrolone (n = 29), and another involved erythropoietin (n = 141).
Three studies (n = 206) tested Neuromuscular Electrical Stimulation. Evidence for effectiveness/efficacy was limited. Strongest
evidence was for multi-component physical activity interventions. However, all studies exhibited at least some concerns for
overall risk of bias, and considering inconsistencies of effect sizes across studies, certainty around true effect sizes is limited.
Conclusion There is currently insufficient evidence for effective interventions to ameliorate changes in muscle function/quan-
tity in hospitalised older adults. Multiple interventions have been safely trialled in heterogeneous populations across different
settings. Treatment may need to be stratified to individual need. Larger scale studies testing combinations of interventions are
warranted. Research aimed at understanding pathophysiology of acute sarcopenia will enable careful risk stratification and
targeted interventions.
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Key points
• A variety of interventions have been trialled for outcome measures relevant to acute sarcopenia.
• There is currently insufficient evidence for effective interventions to treat acute sarcopenia.
• Trials involving a combination of interventions in stratified individually are warranted.
Introduction
Sarcopenia is defined by low muscle strength with low
muscle quantity/quality; additionally demonstrated low
physical performance defines severe sarcopenia. Cut-offs
are two standard deviations (SDs) below means of young
healthy reference populations [1]. Acute sarcopenia (acute
muscle insufficiency) particularly affects hospitalised older
adults [2,3]. Normally proceeded by stressor events, it
is defined by acute declines in muscle quantity/qual-
ity and/or function (strength or physical performance)
producing incident sarcopenia [1,3]. Previous reviews
considered chronic sarcopenia treatment/prevention [4–6];
strongest evidence exists for physical activity. Resistance
training improves muscle quantity, strength and physical
performance in community-dwelling populations [7].
Some trials demonstrated enhanced benefit of nutritional
supplementation alongside [8]. Large studies are underway
evaluating combined nutritional and exercise interventions
for chronic sarcopenia [9].
It is unknown whether chronic sarcopenia interventions
can treat acute sarcopenia. Mechanisms differ, which may
affect treatment efficacy. Acute sarcopenia is associated
with greater systemic inflammation and immune-endocrine
dysregulation. Inflammation (acute or chronic) may blunt
response to exercise or protein challenges (anabolic resis-
tance), but this may be acutely/severely upregulated in acute
sarcopenia [10]. Acute sarcopenia follows an accelerated
course [3]; traditional treatments may not work fast enough.
Additionally, community interventions may be unfeasible in
hospital. This review aimed to identify trialled interventions
for ameliorating negative changes in muscle quantity,
strength or physical performance in hospitalised older adults,
and to summarise/synthesise findings.
Methods
Protocol and registration
Protocol was agreed by all researchers and registered with
Prospective Register of Systematic Reviews—CRD42018112
021. Reporting is consistent with Preferred Reporting Items
for Systematic Reviews and Meta-Analyses guidance.
Eligibility criteria
We included randomised controlled trials (RCTs) and
quasi-RCTs involving hospitalised patients ≥65 years-old,
where pre- and post-intervention measurements of muscle
quantity, strength or physical performance were available.
Post-intervention measures until 28 days post-intervention
were included. We included physical activity, nutritional,
pharmaceutical or Neuromuscular Electrical Stimulation
(NMES) trials. Exclusion criteria were: degenerative neuro-
muscular disorders; acute stroke; trials of parenteral nutri-
tion, surgical technique/invasive procedure, chemother-
apy/radiotherapy, or anaesthetic agents/techniques; no
control group; lengths of stay less than 2 days. We included
studies that measured muscle quantity using computed
tomography (CT), magnetic resonance imaging (MRI),
dual energy X-ray absorptiometry (DXA), bioelectrical
impedance analysis (BIA), or ultrasound, muscle strength
using handgrip strength, knee flexion, or knee extension,
or physical performance using short physical performance
battery (SPPB), gait speed, timed up and go (TUG), or
6-Minute Walking Test (6MWT). There were no date or
language restrictions.
Information sources
We searched electronic databases (MEDLINE, Embase,
CINAHL, CENTRAL) on 16 January 2019; search repeated
on 3 April 2020. Grey literature was identified through
Web of Science, Google Scholar, Clinicaltrials.gov, article
references and protocol citations. We contacted authors
for information where necessary, including requesting age
breakdown of data. If no response was obtained, a decision
was made to include studies where mean age was one
SD > 65.
Search strategy
We used published and unpublished terms for study design
(RCTs), population (older adults AND hospitalised) and
outcome measures (muscle mass OR muscle strength OR
physical performance) in our search. Full search strategy is
available in the online supplement; this was reviewed and
agreed with an information specialist.
Study selection
Citations were imported into Microsoft Excel 2016. Dupli-
cates were removed automatically/manually. Two reviewers
independently screened titles and abstracts for inclusion
(CW, ZM). Disagreements were resolved through discus-
sion. Full texts were reviewed independently by the same
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Data extraction
Data were extracted independently by two reviewers (CW,
ZM) using a template (Microsoft Excel 2016). Extracted
data were country, study design, sample size and dropouts,
sample characteristics (age, ethnicity, body mass index—
BMI, sex), speciality, intervention description (type of inter-
vention, how delivered), intervention characteristics (tim-
ing of intervention, dosage), control group, outcome data,
length of stay and adverse events. Outcome data at baseline
and follow-up to include muscle quantity, muscle strength
and physical performance were extracted.
Risk of bias
Two reviewers (CW, ZM) independently assessed risk of bias
using Cochrane risk of bias tool. Conflicts were resolved by
discussion. Risk of bias was collated using RevMan version
5.3 [11].
Synthesis of results
We summarised study and participant characteristics, and
outcome data at baseline and follow-up using means/SDs in
text and tables. Interventions were grouped by subtype and
outcomes. All studies were included in narrative synthesis. If
sufficient information was available to estimate standardised
mean differences (SMDs) of change scores, effect sizes were
evaluated as described in statistical analysis section. Certainty
of interventions with large effect sizes was evaluated using
Grading of Recommendations, Assessment, Development
and Evaluations [12].
Statistical analysis
Correlations for outcome measures were calculated from
studies reporting SDs of change scores and baseline/
follow-up measures [13]. Mean correlation for each outcome
was used to estimate SD of change in outcomes in studies
where this was not available. We calculated SMDs of
change scores by dividing difference in change score between
comparison and intervention groups by SD of change score
in comparison group [14]. Effect sizes were calculated to
one decimal place and classified as no effect (≤0.1), small
(0.2–0.4), medium (0.5–0.7) or large (0.8 or greater) [15].
If more than one effect size was available for a single trialled
intervention and outcome type, the larger was included.
Meta-analysis was not performed due to high heterogeneity
of interventions and outcomes.
Results
Study selection
We identified 9,805 articles after duplicates removal. We
excluded 9,613 following title/abstract screening; 192 full
texts assessed for eligibility. We excluded 148 full text articles
due to mean age not more than one SD above 65 (n = 56),
no control group (n = 10), follow-up over 28 days (n = 12),
no baseline measures (n = 6), no measures meeting inclusion
criteria (n = 20), duplicate data (n = 11), unable to obtain
necessary data from authors (n = 24), other intervention type
(n = 2), and non-hospitalised population (n = 6) (Figure 1).
We included 44 studies in narrative synthesis and 32 studies
in effect size evaluation.
Study characteristics
This review included 4,522 participants (2,160 control,
2,362 intervention). Sample size per arm ranged from 7
to 232. Most studies were small; 52% (23/44) [17–40]
included 30 or fewer participants per arm; only 9% (4/44)
[41–43] included over 100 participants in both arms. Mean
age across all studies was 79.1 years; 59% female. Of studies
reporting BMI, 74% (20/27) [17, 18, 21, 23, 26–28, 31,
34, 35, 38, 43–51] reported mean overweight (≥25) BMI;
three studies reported mean obese (≥30) BMI in at least
one arm [23, 39, 52]. One study reported data on ethnicity
[38]. Two studies [45, 50] reported frailty prevalence in
control and intervention arms by recognised definitions;
a third reported mean frailty indices [37]. Table 1 shows
included studies’ details; full study characteristics and results
are available online. Table 2 shows effect sizes separated by
interventions and outcomes.
Physical activity interventions
Most studies (61%, 27/44) reported physical activity inter-
ventions. Eighty-nine percent (24/27) included physical per-
formance [17–22, 34, 37, 38, 40–47, 50, 53–58] and 44%
(12/27) included muscle strength [18, 23–25, 36, 43, 44, 46,
47, 54, 57, 58]. One study reported muscle quantity change
[38], a multi-arm trial including nutritional and pharmaceu-
tical interventions. Trials were conducted in various settings
including elective orthopaedic [18, 47], colorectal [20, 25,
46], orthopaedic rehabilitation [19, 21, 54, 58], vascular
[17], and cardiac surgery [40, 44, 55], and geriatric [22,
24, 34, 36, 37, 42, 43, 56, 57], respiratory [23] and general
medicine [38, 41, 45, 53].
A range of physical activity interventions were trialled;
evidence for effect was limited. Interventions included
strength and balance training [21, 38, 40, 44, 46, 56],
early and/or increased mobilisation [17, 20, 22, 24, 25,
41], group exercise [42], water exercise/physiotherapy [18],
chair-based exercise [34, 38], seated side-tapping [47], pedal
exercisers [23, 36] and progressive weight-bearing exercise
in orthopaedic rehabilitation [19, 54, 58], using specialised
harnesses where appropriate. An individualised multimodal
physical training programme involving resistance exercise
using machines and/or weights and gait/balance training
substantially improved physical performance (gait speed and
SPPB) and muscle strength in one of the largest studies [43].
Other trials of individualised physical training programmes
(strength with or without aerobic exercise stratified by
frailty/functional status) showed small effects on physical
performance [37, 45, 53, 55, 57]. Differences may relate
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Figure 1. Flowchart demonstrating identification of included studies. All stages of screening and inclusion/exclusion were performed
in duplicate. Reasons for exclusion of articles reviewed as full texts are specified.
with the largest effect size reported adherence rates of 83.4–
95.8% (≥90% exercises successfully performed each session)
[43] compared to 59.7% (>3 sessions attended per week;
offered daily) in another [57].
Interventions that ameliorated reductions in physical
performance in trial populations included backward walking
[17], progressive exercises stratified by frailty [55], resistance
and balance training [44], chair-based resistance exercise
[38], individually progressed lower limb and core strength-
ening exercise [45], individualised progressive resistance,
balance, and walking exercises [43] and seated side-
tapping [47]. Interventions that ameliorated reductions in
muscle strength included pedal exercise [23], individualised
progressive resistance, balance and walking exercises [43]
and early mobilisation with enhanced recovery after surgery
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Table 1. Characteristics of all studies included in narrative synthesis
Author, date Setting N (control/intervention) Intervention Outcomes
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Physical activity
Busch [44], 2012 Cardiac surgery 64/57 Resistance and balance training TUG
6MWT
Knee extension
Blanc-Bissonb [24], 2008 Geriatric medicine 24/22 Early physiotherapy Handgrip





de Morton [41], 2007 General medicine 126/110 Physiotherapy-designed exercises TUG
Deer [38], 2019 General medicine 20/21 Chair-based and resistance exercise SPPB
DXA FFM
Fioreb [20], 2017 Elective colorectal surgery 22/25 Early mobilisation 6MWT
Giangregorio [19], 2009 Orthopaedic rehabilitation 7/14 Body weight supported treadmill
training
TUG
Henriksenb [25)], 2002 Elective colorectal surgery 12/13 Enhanced recovery Handgrip
Knee extension
Houborg [46], 2006 Elective colorectal surgery 59/60 Strength training programme Gait speed
Handgrip strength
Knee extension
Jones [53], 2006 General medicine 80/80 Individualised progressive exercise TUG
Martinez-Velilla [43], 2019 Geriatric medicine 185/185 Multi-component physical exercise Gait speed
SPPB
Handgrip





McGowanb [36], 2018 Acute medicine for older
people
25/25 Pedal exerciser Knee extension
Knee flexion
Moseley [54], 2009 Orthopaedic rehabilitation 80/80 Weight-bearing exercise Gait speed
Knee extension
Ortiz-Alonso [50], 2019 Geriatric medicine 131/150 Chair-based exercise and walking SPPB




Prasciene [40], 2019 Cardiac surgery 15/14 Balance and resistance training SPPB
6MWT
Rahmann [18], 2009 Elective orthopaedic 20/24 Aquatic physiotherapy TUG
Knee extension
24/21 Water exercise TUG
Knee extension
Raymond [42], 2017 Geriatric medicine 232/236 High-intensity group exercises TUG
Saidb [22], 2012 Geriatric rehabilitation 24/22 Enhanced physical activity TUG
Saidb [56], 2018 Geriatric rehabilitation 93/98 Multimodal exercise programme Gait speed
TUG








Sherrington [58], 2003 Orthopaedic rehabilitation 39/41 Weight-bearing exercise Gait speed
Knee extension
Tal-Akabib [21], 2007 Orthopaedic rehabilitation 29/33 High-intensity exercise TUG
Torres-Sánchez [23], 2017 Respiratory 29/29 Pedal exerciser Knee extension
Wnuk [17], 2016 Vascular 16/15 Backward walking 6MWT
16/16 Forward walking 6MWT
Nutrition
Beelen [48], 2017 General medicine 39/36 Protein-enriched familiar foods SPPB
Handgrip
Knee extension
Bouillanne [30], 2018 Geriatric rehabilitation 14/13 Citrulline amino acid DXA ASMM
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Table 1. Continued
Author, date Setting N (control/intervention) Intervention Outcomes
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
20/20 Whey protein and exercise SPPB
DXA FFM
Ekinci [59], 2016 Orthopaedic surgery 37/38 Beta-hydroxy-beta-
methylbutyrate
Handgrip
Files [39], 2020 Critical care 11/11 Nitrate-rich beetroot juice SPPB













Ogasawara [29], 2018 Respiratory medicine 21/21 EPA-enriched oral
nutritional supplements
BIA SMI




Respiratory medicine 16/17 Oral nutritional supplements Handgrip
Pharmaceutical
Deer [38], 2019 General medicine 20/19 Testosterone SPPB
DXA FFM
Hedström [32], 2004 Orthopaedic surgery 9/11 Growth hormone Knee extension
DXA LBM
Sloan [33], 1992 Orthopaedic surgery 14/15 Nandrolone BIA FFM
Weissberger [31], 2003 Orthopaedic surgery 16/17 Growth hormone Knee flexion
CT thigh CSA
Zhang [60], 2019 Orthopaedic surgery 33/44 EPO injections (females) DXA ASM
25/39 EPO injection (males) DXA ASM
Neuromuscular electrical stimulation
Lopez-Lopez [52], 2019 General medicine 47/48 NMES and exercise
combined
SPPB
Martin-Salvador [35], 2016 Respiratory medicine 20/24 Exercise and NMES
combined
Knee extension
Zinglersen [34], 2018 Geriatric medicine 48/20 Chair-based functional
exercise
Gait speed
8/12 NMES and functional
training
Gait speed
N, participant numbers; ASMM, appendicular skeletal muscle mass; FFM, fat-free mass; SMI, skeletal muscle index; LBM, lean body mass; CSA, cross-sectional
area; LoS, length of hospital stay; COPD, chronic obstructive pulmonary disease. bUnpublished data.
programme was as efficacious as individual sessions; group
exercise resulted in improved therapist efficiency [42]. Group
exercise was embedded into a multimodal physical training
trial [43].
Nutritional interventions
Eleven nutrition trials were identified. Populations included
orthopaedic surgery [27, 59], geriatric [26, 30], general [38,
48, 49, 51], and respiratory medicine [28, 29] and critical
care [39]. Six studies reported physical performance change
[26, 38, 39, 48, 49, 51], seven muscle strength change [26–
28, 48, 49, 51, 59] and four muscle quantity change [27,
29, 30, 38]. Most studies were small; only one included
more than 45 patients per arm. Interventions included
protein-enriched foods [26, 48] or supplements [38, 49,
51], β-Hydroxy-β-MethylButyrate [59], oral nutritional
supplementation [28], eicosapentaenoic acid [29], citrulline
[30], nitrate-rich beetroot juice [49] and nutritional consul-
tation [27]. Three trials combined nutritional consultation
to reach specified caloric/protein intake) with strength/resis-
tance training [27, 38, 51]. One study of progressive strength
training followed by immediate protein supplementation
showed statistically significant improved handgrip strength
[51]. Statistically significant improvements in physical
performance were demonstrated comparing all interventions
in a multi-arm study to placebo, including whey protein
with/without exercise [38].
Pharmaceutical interventions
Five trials involved pharmaceuticals; four in orthopaedic
surgery populations. Pharmaceuticals included growth hor-
mone (GH) [31, 32], steroid (nandrolone) [33], testosterone
[38] and erythropoietin injections [60]. All studies measured
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Table 2. Summary of intervention effect by intervention type, outcome type and effect size
Physical performance Muscle strength
Effect sizea N (con/exp) Risk of Biasb Study Effect sizea N (con/exp) Risk of Biasb Study. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Physical
activity











































+ 20/24 +/− [18] + 20/24 +/− [18]
Seated side-tapping +++ 41/40 − [47] − 41/40 − [47]











































































Protein and exercise +++ 20/20 − [38] + 42/43 − [51]
β-Hydroxy-β-MethylButyrate No data − 37/38 +/− [59]
Oral nutritional
supplementation and snacks
+++ 16/17 +/− [28]
Nutrition consultation
combined with exercise
+ 20/20 +/− [27]
Drugs Testosterone +++ 20/19 − [36] [38]
No data
Growth hormone No data − 9/11 − [32]
NMES NMES in combination with
exercise
+++ 47/48 +/− [52] + 20/24 +/− [35]
N , participant numbers; con, comparison group; exp, intervention group. aEffect sizes categorised as: no effect [−] (≤0.1), small [+] (0.2–0.4), medium [++]
(0.5–0.7), or large [+++] (0.8 or greater). bRisk of Bias categorised according to overall risk as: low [+], some concerns [+/−], or high [−].
measured muscle strength. The only study that measured
physical performance was the multi-arm study including
physical activity and nutritional interventions [38]. One GH
trial showed statistically significant amelioration in muscle
quantity loss by DXA [32] and the other showed statistically
significant amelioration in knee flexion strength loss [31].
Adverse events were similar between control and interven-
tion arms [31]; one study showed slightly higher peripheral
oedema rates amongst GH recipients [32]. The nandrolone
trial did not report statistically significant results [33]. Ery-
thropoietin induced a small statistically significant ameliora-
tion in muscle quantity loss after orthopaedic surgery, not
related to haemoglobin changes. Testosterone was safe in
the multi-arm study, with statistically significant ameliora-
tion in physical performance demonstrated comparing all
intervention groups to placebo [38].
Neuromuscular electrical stimulation
Three trials involved NMES [34, 35, 52]; all combined
NMES with exercise. One trial (geriatric medicine popu-
lation) tested functional training alone against functional
training with NMES [34]. No statistically significant differ-
ent change in gait speed between groups was demonstrated.
Another trial (respiratory medicine population) showed
significant lesser decline in knee extension strength with
NMES [35]. The third trial (general medicine population)
resulted in significant improvements in physical performance
with NMES [52].
Risk of bias and certainty across studies
Figure 2 shows overall risk of bias across studies. Full risk of
bias details is shown in the Supplementary Appendix. There
were at least some concerns for overall risk of bias across most
studies. Adherence to trial intervention was associated with
lowest risk and selection of reported outcome with highest
risk. Most common reason for high risk of bias related to ran-
domisation processes. Over half of studies exhibited at least
some concerns for selection of reported result. Table 3 shows
assessment of certainty for two interventions (individualised




Physical activity interventions were investigated more com-
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Figure 2. Risk of bias results across all included studies.
Table 3. GRADE domain certainty for individual physical training programmes and protein supplementation
GRADE Domain Certainty Comments
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Individual physical training
programme
Risk of bias Moderate RCTs assessed were mainly considered to have some concerns for overall risk of bias; no studies with
high risk of bias.
Imprecision Moderate Meta-analysis of effect sizes across RCTs was not performed, although larger sample sizes in included
studies.
Inconsistency Low Inconsistency of effect sizes across studies.
Indirectness High All but one study in geriatric medicine setting; all in older adults. All patients able to ambulate
pre-admission and at risk of functional decline.
Publication bias High Publication bias of RCTs unlikely, particularly as mixed results presented. Inclusion of thesis and
conference abstract for another physical activity intervention included.
Protein supplementation
(with or without exercise)
Risk of bias Moderate RCTs assessed were considered to have either low risk or some concerns for overall risk of bias.
Imprecision Low Overall small number of studies with low sample sizes.
Inconsistency Moderate Similar effect sizes demonstrated in small numbers of studies.
Indirectness High All studies performed in general/geriatric medicine setting in older adults.
Publication bias High Publication bias of RCTs unlikely, particularly considering identification of studies with low sample size.
with physical performance outcomes; only four trials not
involving physical activity interventions measured physical
performance [26, 39, 48, 49]. Conversely, many physical
activity trials reported muscle strength change but only one
measured muscle quantity change, a multi-arm study also
involving nutritional/pharmaceutical interventions. Nutri-
tional and pharmaceutical trials focused on muscle strength
and quantity changes rather than physical performance. This
suggests disconnect in how physical activity interventions
are trialled compared to other interventions; physical perfor-
mance declines may not be prioritised as organ insufficiency
markers in need of urgent treatment.
Only nine trials reported muscle quantity change. This
relates to historical reduced availability of feasible serial
assessment tools; DXA, CT and MRI remain gold-standard,
but ultrasound is increasingly utilised [1,16]. As sarcope-
nia definition has developed, measures of muscle function
are considered more important than muscle quantity [1].
However, in acute sarcopenia, early muscle quantity declines
may not be associated with muscle strength declines [3];
preventing this may be important to prevent longer term
deteriorations. Additionally, muscle strength may be affected
by fatigue/effort during acute illness making testing of effica-
cy/effectiveness challenging [17]. Muscle quantity may be an
appropriate treatment target in hospitalised patients; future
trials of interventions for acute sarcopenia should consider
incorporating in outcomes. Measurement of muscle quantity
is also important to show biological effectiveness/mechanis-
tic action.
We identified several physical activity interventions that
stratified treatment protocols individually (e.g. by frailty)
[37, 43, 45, 53, 55]. Most substantial and significant effects
on muscle strength and physical performance were demon-
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this demonstrates high adherence of hospitalised older adults
to complex trial designs is possible, effectiveness is expected
to be reduced in clinical environments with limited compli-
ance. Increasing mobilisation alone may be insufficient to
prevent/treat acute sarcopenia [17, 20, 22, 24, 41], although
this is safe to do when possible and should be commended
[17, 20, 24, 25, 41]. Physical activity interventions can
be multidimensional and include resistance exercise [43,
44]; it is safe and feasible to use machines/weights during
acute phase of illness in hospitalised older patients [43, 44,
57]. Pedal exercises [23, 36] and seated side-tapping [47]
are simple, cheap, feasible and potentially effective; these
may be implemented as part of multidimensional stratified
interventions. Group exercise may be as effective as indi-
vidual exercise but more cost-effective [42]. Group exercise
has additional benefits of improving social interaction, and
potentially improving motivation [18] and adherence [43].
Several nutritional interventions were trialled. Although
few trials showed statistically significant results, all trials were
small and may have been under-powered for efficacy. Three
trials combined nutritional intervention with physical activ-
ity [27, 38, 51]. Research in chronic sarcopenia suggested
additional protein supplementation may be most effective
when combined with targeted physical activity i.e. resistance
exercise [19]. As inflammation and anabolic resistance are
heightened with acute illness [3], greater doses (i.e. greater
protein/amino acid intake) may be warranted in hospitalised
older adults.
Few studies tested pharmaceuticals. There is suggestion
from GH trials that this may be effective in ameliorating
reductions in muscle quantity and strength [31, 32]. Further
research is needed, including longer term outcomes. Ben-
efits of GH supplementation need to be balanced against
adverse effects, although supplementation was safe in dosages
used in these small studies. Research is ongoing into novel
pharmaceutical agents for use in acute and chronic sarcope-
nia [20]. Studies assessing correlations between immune-
endocrine biomarkers and phenotypic changes in muscle
quantity, quality or function will enable stratified treatments
and direct potential drug pathways.
Trials of NMES showed conflicting results. NMES
involves delivery of controlled electrical stimuli to superficial
muscles via self-adhesive skin electrodes. These stimuli evoke
muscle contractions, recruiting motor units and activating
muscle fibres [21]. NMES has been shown to ameliorate
reductions in muscle quantity and function in healthy
young volunteers during bed rest [22]. It is plausible that
NMES may treat acute sarcopenia in hospitalised older
adults. However, in establishing effectiveness in clinical
practice, adherence, physical activity impact, and which
muscle groups to stimulate should be considered.
What are the limitations of this review?
This review included hospitalised adults over 65 years-old.
We excluded younger adults to focus towards most vulner-
able patients, who are most likely to benefit from targeted
interventions. More studies were excluded for participant age
than were included (56 versus 44). This suggests persistent
bias against involvement of older people in clinical trials, par-
ticularly those with frailty. Considering we included search
terms for older people in our search, it is likely more trials
involving younger adults were not identified, as well as trials
excluded through abstract screening. Trials conducted in
younger adults may be useful when developing interventions
for acute sarcopenia in older adults, but caution should be
taken extrapolating results from younger less heterogeneous
populations.
It is important to consider only three studies reported
frailty status in both control and intervention arms [37,
45, 50]. Frailty was measured in intervention arms but
rates were not reported in studies that stratified by frailty
[55, 57]. Although important measures, handgrip strength
and gait speed alone may be insufficient to diagnose pre-
morbid frailty during acute illness [42]. Recording levels
of frailty prior to hospitalisation can ensure control and
intervention arms are matched and enable sub-group analysis
assessing treatment effect in individuals with and without
frailty [45]. Only one study reported ethnicity amongst
participants [38]. Normative values of muscle quantity may
vary according to ethnicity [23], and muscle echotexture may
differ [24]. Further research is needed to assess effects of
genetics and environment on ethnic differences, and how
these relate to differences in muscle function and respon-
siveness to interventions. Without information on ethnicity
within published trials, it is not possible to assess for between
group differences.
As described, majority of trials were small; many may
have been underpowered to detect changes. Due to high
heterogeneity in populations, interventions, and outcome
measures, it was not possible to conduct meta-analyses. Some
interventions that were not shown to be effective in small
individual trials may be effective in larger powered studies.
Additionally, most studies exhibited some concerns for risk
of bias overall, and due to inconsistencies in effect sizes across
different studies, there is limited certainty around true effect
sizes. Many different outcome measures were also assessed
across different RCTs. We consider that standardisation of
assessment and outcome measures within geriatric medicine
research will enable greater ease of knowledge transfer,
sharing of datasets and future meta-analyses of RCTs in
ageing.
It is important to consider that none of the included
trials specifically included the presence of (acute or chronic)
sarcopenia as inclusion criteria, or stratified treatment by
sarcopenia. However, we consider that results of identi-
fied RCTs identified will be pivotal towards designing tri-
als for prevention and/or treatment of acute sarcopenia.
Acute sarcopenia is a rapidly progressing research area and
therapeutic target. Twenty-two percent of studies (10/44)
included in this review were published in the last 18 months.
This demonstrates how rapidly progressive this area is, with
increasing numbers of studies measuring muscle quantity
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Conclusion
Deteriorations in muscle quantity, strength and physical
performance are problematic in older adults following hos-
pitalisation. However, insufficient evidence exists to enable
targeted prevention/treatment strategies. A number of inter-
ventions have been trialled and shown to be safe for heteroge-
neous populations across various settings. Multidimensional
physical activity interventions which are individually tailored
(e.g. for frailty) have been trialled [43, 45, 55]; the trial
with most substantial effect size reported excellent adherence
[43]. Large scale multi-arm studies assessing effectiveness of
combined interventions including physical activity [23, 43,
45, 47, 55], NMES [34], nutrition [59] and pharmaceuticals
[31, 32] are warranted. Treatment may be most effective
when stratified according to individual need. Treatment is
likely to be guided by a combination of clinical and biological
factors (e.g. immune-endocrine markers). Further research
aimed at understanding pathophysiology of acute sarcopenia
will enable risk stratification and targeted interventions.
Supplementary data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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